Epidiolex Weighs in at Schedule V

EPIDIOLEX®, a cannabidiol oral solution has been transferred to Schedule V, the lowest restriction classification, by the U.S. Drug Enforcement Administration. But CBD remains on Schedule I, due to its supposed abuse liability.

Russo’s Grand Unified Theory

Dr. Ethan Russo’s research on the Grand Unified Theory (GUT) that discusses how cannabis-based treatment and nutritional approaches can address five conditions that are difficult to treat with conventional medicine.

Meiri Publishes in Nature

In this seminal study, Dr. Dedi Meiri and his team from Israel enhance our knowledge of the content, effect, and variability of cannabinoids across 36 individual cannabis cultivars.

Our Letter to the Editor of JAMA

SCC Board Members oppose several key provisions JAMA wants the state medical boards to adopt.

Beyond-THC Chemovar Evaluation Survey

The Society of Cannabis Clinicians developed a survey in 2011 that asked about patients’ responses to CBD-rich cannabis.

SCC Hears McAllister On Cannabis Cancer Research

Researchers have discovered that CBD (Cannabidiol) is a very potent inhibitor of breast cancer metastasis. Doctors who monitor cannabis use by patients were bursting with questions during a talk by Sean McAllister, PhD, who has been studying the anti-cancer effects of cannabinoids in the laboratory.